12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Imgatuzumab: Development discontinued

Roche disclosed in its 2Q13 earnings that it discontinued development of GA201 to treat solid tumors. The pharma said data from a Phase II trial in 160 patients with metastatic colorectal cancer showed that...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >